Shares of TrovaGene Inc. (NASDAQ: TROV), a developer of patented technology for the detection of transrenal DNA and RNA, have risen sharply in trading today.
At last check, TROV shares were trading 15.38% higher at $3.75 on above average volume of 146,792. The stock touched an intra-day high of $3.80 today.
Last week, TrovaGene announced the full exercise of the over-allotment option granted to its underwriters to purchase 172,500 additional units at a public offering price of $8 per unit. The over-allotment option was granted in connection with TROV’s previously announced public offering of 1,150,000 units. The company’s gross proceeds from the offering totaled $10,580,000.